SLC5A2 and metabolic syndrome: Logistic regression analyses revealed that SGLT2 inhibitor initiation had correlation with younger age, higher BMI, higher HbA1c, better kidney function, dyslipidemia, no history of hypertension and use of ACEI/ARBs and statins (Supplementary Fig. S1).